NYSE:BSX - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	19,297	3,271	3,865	4,315	25
12/31/2025	17,590	2,733	2,915	3,744	31
12/31/2024	15,996	2,201	2,251	2,941	31
3/31/2024	14,707	1,765	1,726	2,477	N/A
12/31/2023	14,240	1,570	1,822	2,503	N/A
9/30/2023	13,757	1,191	1,736	2,353	N/A
6/30/2023	13,400	861	1,559	2,125	N/A
3/31/2023	13,045	846	1,256	1,774	N/A
12/31/2022	12,682	642	1,008	1,526	N/A
9/30/2022	12,567	596	629	1,197	N/A
6/30/2022	12,329	828	668	1,192	N/A
3/31/2022	12,162	754	1,007	1,528	N/A
12/31/2021	11,888	985	1,398	1,870	N/A
9/30/2021	11,470	1,101	1,701	2,065	N/A
6/30/2021	11,196	526	1,939	2,243	N/A
3/31/2021	10,122	201	1,604	1,869	N/A
12/31/2020	9,913	-115	1,219	1,508	N/A
9/30/2020	10,108	3,685	1,242	1,527	N/A
6/30/2020	10,157	3,980	1,008	1,386	N/A
3/31/2020	10,785	4,287	986	1,409	N/A
12/31/2019	10,735	4,700	1,427	1,836	N/A
9/30/2019	10,392	1,090	782	1,163	N/A
6/30/2019	10,077	1,396	826	1,162	N/A
3/31/2019	9,937	1,797	148	467	N/A
12/31/2018	9,823	1,671	-6	310	N/A
9/30/2018	9,670	670	686	975	N/A
6/30/2018	9,500	521	653	926	N/A
3/31/2018	9,267	112	1,359	1,626	N/A
12/31/2017	9,048	104	N/A	1,426	N/A
9/30/2017	8,831	843	N/A	1,418	N/A
6/30/2017	8,714	788	N/A	935	N/A
3/31/2017	8,582	435	N/A	1,059	N/A
12/31/2016	8,386	347	N/A	1,182	N/A
9/30/2016	8,095	81	N/A	835	N/A
6/30/2016	7,878	-345	N/A	1,274	N/A
3/31/2016	7,595	-36	N/A	913	N/A
12/31/2015	7,477	-239	N/A	691	N/A
9/30/2015	7,314	-396	N/A	711	N/A
6/30/2015	7,272	-155	N/A	649	N/A
3/31/2015	7,302	-253	N/A	874	N/A
12/31/2014	7,308	-119	N/A	1,269	N/A
9/30/2014	7,258	288	N/A	1,104	N/A
6/30/2014	7,147	240	N/A	1,009	N/A
3/31/2014	7,083	366	N/A	1,121	N/A
12/31/2013	7,070	-121	N/A	1,110	N/A
9/30/2013	7,126	-168	N/A	1,204	N/A
6/30/2013	7,125	-827	N/A	1,225	N/A

アナリストによる今後の成長予測

収入対貯蓄率: BSXの予測収益成長率 (年間18.2% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: BSXの収益 ( 18.2% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: BSXの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: BSXの収益 ( 8.9% ) US市場 ( 8.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: BSXの収益 ( 8.9% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: BSXの自己資本利益率は、3年後には低くなると予測されています ( 16.8 %)。

Boston Scientific 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Price target increased by 8.9% to US$79.72

Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Price target increased by 8.5% to US$69.67

Boston Scientific Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2024

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Boston Scientific Corporation Provides Earnings Guidance for the Full Year 2023

Recent updates

Boston Scientific Has Become A Standout Growth Story In Med-Tech

Why We're Not Concerned About Boston Scientific Corporation's (NYSE:BSX) Share Price

Senior VP notifies of intention to sell stock

Is Boston Scientific (NYSE:BSX) Using Too Much Debt?

Boston Scientific Corporation Appoints Cheryl Pegus to its Board of Directors

Price target increased by 8.9% to US$79.72

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Boston Scientific Corporation Provides Earnings Guidance for the Second Quarter and Full Year of 2024

Boston Scientific (NYSE:BSX) Is Reinvesting At Lower Rates Of Return

Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash

Key Executive notifies of intention to sell stock

Boston Scientific Corporation to Report Q1, 2024 Results on Apr 24, 2024

A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Boston Scientific Corporation, Annual General Meeting, May 02, 2024

We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease

Chairman exercised options and sold US$1.5m worth of stock

Full year 2023 earnings: EPS exceeds analyst expectations

What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E

Is Boston Scientific (NYSE:BSX) A Risky Investment?

Price target increased by 8.5% to US$69.67

Boston Scientific Corporation Announces Executive Changes, Effective March 1, 2024

Now 22% overvalued after recent price rise

Boston Scientific Corporation Provides Earnings Guidance for the First Quarter and Full Year of 2024

Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital

Boston Scientific: Portfolio Updates Driving Top-Line Growth

Boston Scientific: Continued M&A Drives More Growth

BBoston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) from a group of shareholders for $3.6 billion.

Boston Scientific Corporation (NYSE:BSX) entered into a definitive agreement to acquire Axonics, Inc. (NasdaqGS:AXNX) for $3.7 billion.

Boston Scientific Corporation to Report Q4, 2023 Results on Jan 31, 2024

Insider notifies of intention to sell stock

Boston Scientific Corporation Initiates AVANT GUARD Clinical Trial to Evaluate FARAPULSE™ Pulsed Field Ablation System as First-Line Treatment for Persistent Atrial Fibrillation

Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?

Nelda J. Connors and David J. Roux Not to Stand for Re-Election as Members of the Board of Directors of Boston Scientific Corporation

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of Relievant Medsystems, Inc.

Chairman notifies of intention to sell stock

Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?

Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue

Boston Scientific Corporation Provides Earnings Guidance for the Fourth Quarter and Full Year of 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal AGENT IDE Clinical Trial of the AGENT™ Drug-Coated Balloon

Chairman exercised options and sold US$4.2m worth of stock

Boston Scientific Corporation Provides Earnings Guidance for the Full Year 2023

Chairman exercised options and sold US$4.4m worth of stock

Boston Scientific Corporation Announces FDA Approval for the Latest-Generation watchMAN FLX Pro Left Atrial Appendage Closure Device

Boston Scientific Corporation to Report Q3, 2023 Results on Oct 26, 2023

ADVENT Offers Up An Early Present For Boston Scientific Investors

Boston Scientific Corporation Announces Positive 12-Month Results from the Pivotal Advanced Clinical Trial of the FARAPULSE™ Pulsed Field Ablation System

Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)

Boston Scientific Corporation Receives FDA Approval for the POLARx™ Cryoablation System

New minor risk - Earnings quality

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Boston Scientific Corporation (NYSE:BSX) agreed to acquire EV Business and B Braun of Aesculap AG for €47 million.

Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly

Boston Scientific Remains Operationally Sound But May Have Limited Upside

Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital

Boston Scientific Corporation to Report Q2, 2023 Results on Jul 27, 2023

Boston Scientific Corporation (NYSE:BSX) completed the acquisition of an additional stake in M.I.TECH Co.,Ltd (KOSDAQ:A179290) from Synergy Innovation Co., Ltd. (KOSDAQ:A048870)

Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate

Insider exercised options and sold US$2.3m worth of stock

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Insider recently sold US$2.8m worth of stock

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider exercised options and sold US$238k worth of stock

Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly

Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture

Insider notifies of intention to sell stock

Insider exercised options and sold US$210k worth of stock

Chairman exercised options and sold US$387k worth of stock